{"id":"typhoid-vaccine","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Injection site pain or swelling"},{"rate":"1–5","effect":"Fever"},{"rate":"1–3","effect":"Headache"},{"rate":"1–3","effect":"Myalgia"},{"rate":"5–10","effect":"Gastrointestinal upset (oral formulation)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains either live attenuated (weakened) or inactivated typhoid bacteria, or purified polysaccharide capsular antigen, which triggers both humoral and cell-mediated immune responses. This allows the body to recognize and mount a rapid defense against natural infection with S. typhi, preventing or reducing the severity of typhoid disease.","oneSentence":"The typhoid vaccine stimulates the immune system to produce antibodies and cellular immunity against Salmonella typhi, the bacterium that causes typhoid fever.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:36:22.692Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of typhoid fever in endemic regions and travelers"}]},"trialDetails":[{"nctId":"NCT03971669","phase":"PHASE4","title":"Blood Donor CVD 5000","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2004-01-16","conditions":"Risk Reduction","enrollment":150},{"nctId":"NCT05500482","phase":"PHASE4","title":"Vellore Typhoid Vaccine Impact Trial","status":"COMPLETED","sponsor":"Christian Medical College, Vellore, India","startDate":"2023-05-01","conditions":"Typhoid Fever","enrollment":72400},{"nctId":"NCT06663436","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Diarrhoea","enrollment":200},{"nctId":"NCT06455852","phase":"NA","title":"Vaccine- and Infection-derived Correlates of Protection for Cholera.","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-03-02","conditions":"Cholera","enrollment":1221},{"nctId":"NCT07286370","phase":"PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-02-16","conditions":"Salmonella Infections","enrollment":537},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT03970304","phase":"PHASE4","title":"CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2013-10-24","conditions":"Typhoid Vaccination","enrollment":87},{"nctId":"NCT07320716","phase":"PHASE2","title":"Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-01-02","conditions":"Diarrhoea","enrollment":528},{"nctId":"NCT05919472","phase":"NA","title":"Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women","status":"COMPLETED","sponsor":"Nicole Stoffel","startDate":"2023-07-01","conditions":"Iron Deficiency Anemia","enrollment":180},{"nctId":"NCT06817421","phase":"PHASE4","title":"Opportunistic Pneumococcal Immunisation Trial in MALnutrition","status":"NOT_YET_RECRUITING","sponsor":"Nick Fancourt","startDate":"2026-01","conditions":"Severe Acute Malnutrition in Childhood, Pneumococcal Disease, Pneumococcal Vaccines","enrollment":214},{"nctId":"NCT04543877","phase":"EARLY_PHASE1","title":"WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study","status":"COMPLETED","sponsor":"USDA, Western Human Nutrition Research Center","startDate":"2022-09-27","conditions":"Inflammation, Vaccine, Intestinal Permeability","enrollment":60},{"nctId":"NCT06630884","phase":"PHASE1","title":"Inflammatory Challenge and Fear","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-28","conditions":"Posttraumatic Stress Disorder (PTSD)","enrollment":288},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT05480800","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-09-13","conditions":"Salmonella Infections","enrollment":155},{"nctId":"NCT04083950","phase":"EARLY_PHASE1","title":"Induction of Gut Permeability by an Oral Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"USDA, Western Human Nutrition Research Center","startDate":"2019-12-04","conditions":"Intestinal Permeability, Inflammation, Vaccine","enrollment":10},{"nctId":"NCT04349553","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Enteric Fever Vaccine","status":"COMPLETED","sponsor":"Prokarium Ltd","startDate":"2019-12-16","conditions":"Enteric Fever","enrollment":46},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT05745987","phase":"PHASE4","title":"Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT","status":"RECRUITING","sponsor":"McMaster University","startDate":"2024-09-17","conditions":"Monkeypox","enrollment":3000},{"nctId":"NCT06718127","phase":"NA","title":"Description of the Immune Response to Yellow Fever Vaccination","status":"RECRUITING","sponsor":"Institut Pasteur","startDate":"2024-09-30","conditions":"Immunization, Infections","enrollment":38},{"nctId":"NCT03705585","phase":"PHASE4","title":"CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2018-11-05","conditions":"Typhoid and/or Cholera Vaccination","enrollment":240},{"nctId":"NCT04741828","phase":"PHASE2, PHASE3","title":"Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2021-05-03","conditions":"Vaccine","enrollment":188},{"nctId":"NCT03299426","phase":"PHASE3","title":"Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2018-02-21","conditions":"Typhoid","enrollment":30000},{"nctId":"NCT03614533","phase":"PHASE2","title":"Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2018-12-03","conditions":"Typhoid","enrollment":251},{"nctId":"NCT06757283","phase":"PHASE3","title":"ZyVac-TCV Bangladesh Study","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-04-01","conditions":"Typhoid Vaccination, Typhoid, Typhoid Fever","enrollment":4000},{"nctId":"NCT05613205","phase":"PHASE1","title":"Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-11-28","conditions":"Typhoid Fever","enrollment":97},{"nctId":"NCT05475379","phase":"PHASE1, PHASE2","title":"Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2022-07-01","conditions":"Typhoid","enrollment":630},{"nctId":"NCT02868970","phase":"PHASE4","title":"Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-02-15","conditions":"Healthy","enrollment":2404},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT06104345","phase":"PHASE4","title":"Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2023-10-25","conditions":"Vaccine-Preventable Diseases, Typhoid Fever, Cholera","enrollment":65},{"nctId":"NCT03917654","phase":"PHASE2","title":"Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-24","conditions":"Malaria","enrollment":1301},{"nctId":"NCT02415387","phase":"EARLY_PHASE1","title":"Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2014-01-01","conditions":"Cognitive Side Effects of Cancer Therapy, Depression, Recurrent Breast Carcinoma","enrollment":172},{"nctId":"NCT02429531","phase":"PHASE4","title":"Polysaccharide Antibody Response Study","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2015-10","conditions":"Specific Polysaccharide Antibody Deficiency","enrollment":200},{"nctId":"NCT00679172","phase":"PHASE2","title":"Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2008-05","conditions":"Typhoid","enrollment":187},{"nctId":"NCT03968211","phase":"PHASE1","title":"Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2019-07-01","conditions":"Immune Deficiency","enrollment":37},{"nctId":"NCT04852185","phase":"PHASE4","title":"Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana","status":"RECRUITING","sponsor":"International Vaccine Institute","startDate":"2021-08-24","conditions":"Typhoid Fever","enrollment":23000},{"nctId":"NCT06116669","phase":"NA","title":"Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women","status":"UNKNOWN","sponsor":"Swiss Federal Institute of Technology","startDate":"2023-11-01","conditions":"Iron Deficiency Anemia","enrollment":180},{"nctId":"NCT06027801","phase":"NA","title":"Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2023-09-06","conditions":"Iron Deficiency Anemia","enrollment":150},{"nctId":"NCT05771779","phase":"PHASE3","title":"Co-administration Study of OCV, TCV and MR","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2023-10-14","conditions":"Typhoid, Cholera, Measles","enrollment":2117},{"nctId":"NCT02391909","phase":"","title":"Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2015-08-26","conditions":"Typhoid Fever","enrollment":855},{"nctId":"NCT01405521","phase":"PHASE2","title":"Understanding Typhoid Disease After Vaccination","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2011-10-07","conditions":"Typhoid Fever, Enteric Fever, Typhoid","enrollment":99},{"nctId":"NCT05119426","phase":"PHASE4","title":"Effectiveness of a Typhoid Conjugate Vaccine in DRC","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2022-02-11","conditions":"Typhoid Fever","enrollment":48000},{"nctId":"NCT03523767","phase":"PHASE1","title":"Effect of Systemic Inflammation on Emotion and Cognition in Patients With Mood Disorder - A Vaccine Study","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-02-07","conditions":"Major Depressive Disorder","enrollment":19},{"nctId":"NCT05346302","phase":"EARLY_PHASE1","title":"Persistent Readiness Through Early Prediction Immunization Study","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2022-02-08","conditions":"Inflammatory Response","enrollment":249},{"nctId":"NCT05562102","phase":"","title":"TyVECO: Surveillance Protocol","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2021-08-09","conditions":"Typhoid Fever, Intestinal Perforation","enrollment":48000},{"nctId":"NCT02715635","phase":"PHASE1","title":"Influence of Dietary Nitrate on Vascular Dysfunction and Inflammation","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2016-04","conditions":"Cardiovascular Diseases","enrollment":78},{"nctId":"NCT02324751","phase":"PHASE2","title":"Vaccines Against Salmonella Typhi","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-09","conditions":"Typhoid Fever, Enteric Fever","enrollment":112},{"nctId":"NCT00875524","phase":"PHASE2","title":"Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-03","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":180},{"nctId":"NCT04051268","phase":"PHASE3","title":"Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2020-03-02","conditions":"Safety Issues, Immunogenicity","enrollment":3071},{"nctId":"NCT03889158","phase":"PHASE4","title":"Effect of Age and Fitness on Vascular Function and Oxidative Stress During Acute Inflammation","status":"TERMINATED","sponsor":"University of Illinois at Chicago","startDate":"2019-03-25","conditions":"Aging, Inflammation","enrollment":35},{"nctId":"NCT04830371","phase":"PHASE2, PHASE3","title":"Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2020-09-07","conditions":"Typhoid Fever","enrollment":444},{"nctId":"NCT03554213","phase":"","title":"Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India","status":"COMPLETED","sponsor":"Stanford University","startDate":"2018-07-02","conditions":"Enteric Fever, Typhoid Fever, Salmonella Typhi Infection","enrollment":17292},{"nctId":"NCT04204096","phase":"PHASE3","title":"Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2020-02-04","conditions":"Typhoid","enrollment":1800},{"nctId":"NCT03527355","phase":"PHASE2","title":"Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2018-04-18","conditions":"Typhoid","enrollment":285},{"nctId":"NCT03048929","phase":"EARLY_PHASE1","title":"Inflammation and Threat Sensitivity in PTSD","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-04-01","conditions":"Posttraumatic Stress Disorder","enrollment":30},{"nctId":"NCT03421236","phase":"PHASE1","title":"Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)","status":"UNKNOWN","sponsor":"Patrice Jichlinski","startDate":"2018-02-18","conditions":"Non Muscle Invasive Bladder Cancer","enrollment":25},{"nctId":"NCT03600025","phase":"PHASE1","title":"Cellular Immune Responses in Typhoid Fever Patients and Vaccinees","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2018-07-15","conditions":"Typhoid Fever Patients and Healthy Volunteers to Receive Typbar-TCV Vaccine","enrollment":30},{"nctId":"NCT02645032","phase":"PHASE1","title":"Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2016-05-19","conditions":"Typhoid","enrollment":144},{"nctId":"NCT03933098","phase":"PHASE3","title":"Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2019-11-15","conditions":"Typhoid","enrollment":1800},{"nctId":"NCT03460405","phase":"PHASE2","title":"Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2018-07-16","conditions":"Safety Issues, Immunogenicity","enrollment":600},{"nctId":"NCT03956524","phase":"PHASE1","title":"Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2019-03-16","conditions":"Typhoid Fever","enrollment":75},{"nctId":"NCT02338752","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Mix Vaccine in Pancreatic Carcinoma Patient","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-01","conditions":"Pancreatic Neoplasms","enrollment":20},{"nctId":"NCT03294564","phase":"EARLY_PHASE1","title":"Cognitive, Emotional, and Neural Responses to Acute Inflammation","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-01-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT03926455","phase":"PHASE1","title":"Safety and Immunogenicity of Typhax, a Typhoid Vaccine","status":"COMPLETED","sponsor":"Matrivax Research and Development Corporation","startDate":"2016-03-28","conditions":"Typhoid Fever","enrollment":45},{"nctId":"NCT02628054","phase":"NA","title":"Investigating the Effects of Typhoid Vaccine on Sleep in Healthy Volunteers","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-02","conditions":"Typhoid Vaccine on Sleep","enrollment":16},{"nctId":"NCT03109600","phase":"PHASE1","title":"Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2017-04-18","conditions":"Safety Issues","enrollment":100},{"nctId":"NCT02286544","phase":"PHASE1","title":"Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2014-10","conditions":"Myocardial Infarction, Inflammation, Acute Coronary Syndrome (ACS)","enrollment":36},{"nctId":"NCT00386789","phase":"","title":"Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2006-10-05","conditions":"Typhoid Fever","enrollment":""},{"nctId":"NCT00277147","phase":"PHASE1","title":"Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2006-01-09","conditions":"Typhoid Fever","enrollment":25},{"nctId":"NCT01582321","phase":"EARLY_PHASE1","title":"Investigation of the Influence of Gender on Cardiovascular Function","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2012-03","conditions":"Cardiovascular Function","enrollment":56},{"nctId":"NCT00197249","phase":"PHASE3","title":"Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-05","conditions":"Hepatitis A","enrollment":1034},{"nctId":"NCT02175420","phase":"NA","title":"Role of BCG as Booster Vaccination","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2012-07","conditions":"BCG Vaccination","enrollment":30},{"nctId":"NCT02338804","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Mix Vaccine in Breast Carcinoma Patient","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-01","conditions":"Breast Neoplasms","enrollment":20},{"nctId":"NCT02338778","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Mix Vaccine in Hepatocyte Carcinoma Patient","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-01","conditions":"Liver Neoplasms","enrollment":20},{"nctId":"NCT02338700","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Mix Vaccine in Prostate Carcinoma Patient","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-01","conditions":"Prostatic Neoplasms","enrollment":20},{"nctId":"NCT00751933","phase":"PHASE2","title":"Vaccines and Dietary Oats in the Treatment of Ulcerative Colitis","status":"TERMINATED","sponsor":"Haukeland University Hospital","startDate":"2008-10","conditions":"Ulcerative Colitis","enrollment":3},{"nctId":"NCT01608815","phase":"PHASE3","title":"Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-05","conditions":"Salmonella Infections, Typhoid Fever, Bacterial Infections","enrollment":200},{"nctId":"NCT00326443","phase":"PHASE1","title":"CVD 909 Vi Prime Boost Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"Typhoid Fever","enrollment":21},{"nctId":"NCT02121145","phase":"PHASE4","title":"Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines","status":"UNKNOWN","sponsor":"Helsinki University Central Hospital","startDate":"2013-10","conditions":"Healthy","enrollment":100},{"nctId":"NCT01533285","phase":"EARLY_PHASE1","title":"Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder Patients","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2012-05","conditions":"Major Depressive Disorder","enrollment":40},{"nctId":"NCT01438996","phase":"PHASE2","title":"Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-10","conditions":"Typhoid Fever","enrollment":51},{"nctId":"NCT01466387","phase":"PHASE3","title":"A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-11","conditions":"Meningococcal Disease, Meningococcal Meningitis, Typhoid","enrollment":552},{"nctId":"NCT01193907","phase":"PHASE2","title":"Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-10","conditions":"Typhoid Fever","enrollment":88},{"nctId":"NCT01123941","phase":"PHASE1","title":"Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-05","conditions":"Typhoid Fever","enrollment":50},{"nctId":"NCT00342628","phase":"PHASE2","title":"Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2006-07","conditions":"Typhoid Fever","enrollment":301},{"nctId":"NCT01019083","phase":"PHASE1, PHASE2","title":"Studies of Immune Responses to Orally Administered Vaccines in Developing Country","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2008-02","conditions":"Cholera, Typhoid","enrollment":1016},{"nctId":"NCT00269295","phase":"PHASE1, PHASE2","title":"TY800 Dose Escalation (Typhoid)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"Typhoid and Paratyphoid Fevers","enrollment":47},{"nctId":"NCT00125047","phase":"PHASE4","title":"Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2001-10","conditions":"Typhoid, Paratyphoid Fever","enrollment":27231},{"nctId":"NCT00125008","phase":"PHASE4","title":"Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2003-05","conditions":"Typhoid, Paratyphoid Fever","enrollment":37673},{"nctId":"NCT00498654","phase":"PHASE2","title":"Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Avant Immunotherapeutics","startDate":"2007-07","conditions":"Typhoid Fever","enrollment":180},{"nctId":"NCT00131820","phase":"PHASE4","title":"Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2001-12","conditions":"Typhoid, Paratyphoid Fever","enrollment":100742},{"nctId":"NCT00131833","phase":"PHASE4","title":"Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2001-10","conditions":"Typhoid, Paratyphoid Fever","enrollment":96468}],"_emaApprovals":[],"_faersSignals":[{"count":8,"reaction":"MALAISE"},{"count":6,"reaction":"DIZZINESS"},{"count":6,"reaction":"DRUG EXPOSURE DURING PREGNANCY"},{"count":6,"reaction":"NAUSEA"},{"count":6,"reaction":"OFF LABEL USE"},{"count":5,"reaction":"PYREXIA"},{"count":4,"reaction":"ALOPECIA"},{"count":4,"reaction":"ANXIETY"},{"count":4,"reaction":"DRUG HYPERSENSITIVITY"},{"count":4,"reaction":"FATIGUE"}],"_approvalHistory":[],"publicationCount":803,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Typhim Vi®","Typhim Vi","Typhoid Vi Polysaccharide Vaccine"],"phase":"marketed","status":"active","brandName":"Typhoid Vaccine","genericName":"Typhoid Vaccine","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Biologic","firstApprovalDate":"","aiSummary":"The Typhoid Vaccine is a vaccine component that targets Salmonella Typhi, a bacterium causing typhoid fever. It has been studied in clinical trials, including a Phase 2a study evaluating its safety, reactogenicity, and immune response against invasive nontyphoidal Salmonella disease and typhoid fever in infants.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}